Tisotumab Vedotin demonstrates superior survival outcomes in Advanced Cervical Cancer

Eisai Announces independent development and commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)

Daiichi Sankyo secures $47M in ADC Patent arbitration against Seagen, faces upcoming conflict with Pfizer